Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, postponed its IPO on Friday, citing poor market conditions.
The Burnaby, Canada-based company was founded in 1996 and booked $27 million in sales for the 12 months ended June 30, 2014. XENE. Xenon Pharmaceuticals initially filed confidentially on 8/16/2013. Jefferies & Co. and Wells Fargo Securities were set to be the joint bookrunners on the deal.
